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Novelty and Impact: Previous studies of the inverse association of statins and liver cancer have not 
considered well the effect of main indication and contraindication of statins, meanwhile a study taking 
account of these factors found no association. Our study based on two large independent populations, 
different study designs, and adjusting for important covariates, found a consistent inverse association 
between statins and liver cancer which was only seen for hepatocellular carcinoma but not 




Epidemiological studies of statin use and liver cancer risk have produced conflicting results.  We 
examined the association between statin use and risk of primary liver cancer in two large independent 
study populations taking account of important covariates and main indications of statins such as high 
cholesterol and chronic liver disease. We performed a nested case-control study within the Scottish 
Primary Care Clinical Informatics Unit (PCCIU) database.  Five controls were matched to cases with 
primary liver cancer and we used conditional logistic regression to calculate odds ratios (ORs) and 
95% confidence intervals (CIs) for associations with statin use. We also conducted a prospective 
cohort study within the UK Biobank using self-reported statin use and cancer-registry recorded 
primary liver cancer outcomes. Cox regression was used to calculate hazard ratios (HRs) and 95% 
CIs. In the PCCIU case-control analysis, 434 liver cancer cases were matched to 2,103 controls. In the 
UK Biobank cohort, 182 out of 475,768 participants developed incident liver cancer. Statin use was 
associated with 39% lower risk of liver cancer in the PCCIU (adjusted OR 0.61, 95% CI 0.43-0.87). 
When we examined specific subtypes of liver cancer in the UK Biobank, statin use was associated 
with lower risk of hepatocellular carcinoma (HCC) (adjusted HR, 0.48; 95% CI, 0.24-0.94) but not 
intrahepatic bile duct carcinoma (IBDC) (adjusted HR, 1.09; 95% CI, 0.45-2.64). In conclusion, we 
found a consistent inverse relationship between statin use and risk of primary liver cancer which was 




Liver cancer (85-90% hepatocellular carcinoma [HCC]) is a rapidly increasing, highly fatal cancer.1 
In the United States, age-adjusted mortality rates for liver cancer increased by 43% between 2000 and 
2016.2 Increasing secular trends in incidence and mortality have been observed across many countries 
including the United Kingdom3, Poland,  Brazil, Germany and Norway.4 Major risk factors for liver 
cancer include hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, heavy alcohol 
drinking, and non-alcoholic fatty liver disease (NAFLD).5,6 With further increases in liver cancer 
incidence predicted,7 there is growing interest in identifying modifiable risk factors for liver cancer, 
especially those that can be targeted with medications, such as aspirin and nonsteroidal anti-
inflammatory drugs (NSAIDs). Use of statins (or 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors), commonly used because of their efficacy in preventing cardiovascular morbidity and 
mortality, has been shown to be inversely related to risk of various cancers.8–11  
 
There is increasing evidence from epidemiological studies of an inverse relationship between statin 
use and the risk of liver cancer. Results from recent systematic reviews and meta-analyses show that, 
compared with non-users of statins, individuals using statins have 40%-50% lower risk of liver 
cancer.11–13 However, there remains unexplained high between-study heterogeneity that affects the 
statistical validity of the summary estimates of effect reported in these studies. Stratification on, for 
example, histological type (HCC, intrahepatic bile duct carcinoma [IBDC]), risk factors (HCV and 
HBV infection, alcohol abuse, NAFLD, and type 2 diabetes), study design and study location, has 
provided some information on the topic. Nonetheless, other methodological considerations, risk 
factors, and important indications and contraindications of statin use have not been well studied.  
 
We therefore examined the association between use of statins and the risk of primary liver cancer 





Primary Care Clinical Informatics Unit (PCCIU) database 
Data source 
The Primary Care Clinical Informatics Unit (PCCIU) database is an electronic primary care dataset 
that captures approximately 15% of the Scottish population from 2000 to 2011.14 Demographics and 
details of patient encounters, clinical diagnosis (using Read codes)15 by General Practitioners (GPs), 
and prescriptions were collected routinely for every patient. Data access was approved by the 
Research Applications and Data Management Team of the University of Aberdeen, and we obtained 
ethical approval for this analysis from the School of Medicine, Dentistry and Biomedical Sciences 
Research Ethics Committee at Queen’s University Belfast (reference number: 15.43). 
 
Study design 
A nested case-control study within the PCCIU database was conducted. Cases were defined as having 
the first diagnosis of primary liver cancer, including HCC and IBDC, (based upon GP Read code: 
B15, excluding B153) between January 1, 1999 and April 30, 2011. Up to five controls were matched 
to each case on exact year of birth, sex and GP’s practice. We defined the index date as the date of 
liver cancer diagnosis for cases and the date of the index case’s liver cancer diagnosis for matched 
controls. Cases and controls had to be free from other cancer (excluding non-melanoma skin cancer) 
prior to their index date.  
 
The start of prescription records was considered January 1, 1996 (as prescriptions prior to this date 
were less likely to have been electronically recorded) or the date of patient registration at a GP 
practice if this occurred after January 1, 1996. The shortest duration of available prescription records 
was determined within each matched set of a case and its controls. The start of the exposure period 
was then set as the index date minus this duration within each matched set of a case and controls to 
ensure all members of the matched set had an identical length of exposure period. The end of the 
exposure period was one year prior to the index date to reduce the potential for reverse causation due 
to increased exposure to healthcare professionals following cancer symptoms.16 Cases and controls 
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Medication use was determined from GP prescriptions in the exposure period. We extracted 
prescriptions for statins17 (including atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin, 
cerivastatin). Defined daily doses (DDD) were calculated from the quantity of tablets and strength, as 
defined by World Health Organization.18 Comorbidities were obtained from GP diagnosis codes prior 
to the index date, including diabetes, coronary heart disease, myocardial infarction, heart failure, 
peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, mental illness, gastro-
oesophageal reflux disease, peptic ulcer disease, and liver diseases (hepatitis, cirrhosis, alcoholic fatty 
liver, non-alcoholic fatty liver, biliary cirrhosis). Proton pump inhibitors (PPIs), histamine 2-receptor 
antagonists (H2RA), beta-adrenoceptor blocking drugs, nonsteroidal anti-inflammatory drugs 
(NSAID) and aspirin use was identified from prescription records. Lifestyle risk factors were 
extracted from GP records including smoking status (never smoker, previous smoker, and current 
smoker), alcohol consumption (none, low [moderate or light drinker], or high intake [above 
recommended limits, chronic alcoholism]), and obesity (body mass index [BMI]>30], or not obese) 
using the most recent record prior to the index date. Postcode of each GP practice was used to assign 




The UK Biobank is a cohort health resource containing approximately 500,000 volunteer participants 
aged 40 to 69 from England, Scotland and Wales recruited from 2006 to 2010.20 A wide range of data 
was collected at baseline including lifestyle, environmental, medical history and physical measures, 
along with biological samples. The UK Biobank is linked to cancer registry data from the Health and 
Social Care Information Centre (in England and Wales) and the National Health Service Central 
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Register (in Scotland). The UK Biobank has ethical approval from the North West Multi-Centre 
Research Ethics Committee. All participants provided written informed consent. 
 
Study design 
We conducted a prospective cohort study among participants in the UK Biobank. Liver cancer cases 
were identified using cancer registry records (based upon ICD 10 codes C22, liver and intrahepatic 
bile duct cancer) up to September 30, 2014. Participants with a cancer diagnosis (apart from non-
melanoma skin cancer) prior to baseline or in the year after baseline were excluded (as these cancers 
may have been present at baseline). Consequently, cohort participants were followed from one year 
after baseline until the date of liver cancer diagnosis or censoring (on the earliest of the date of death, 
date of other cancer, or September 30, 2014). 
 
Data collection 
Participants reported history of statin use was collected by using a touchscreen questionnaire at 
baseline at UK Biobank Assessment Centres, and then verified during verbal interview with a UK 
Biobank nurse. Data on demographic and lifestyle factors were also determined from patient 
interview and touch screen at baseline, including age, sex, comorbidities (diabetes, hypertension, high 
cholesterol, angina, myocardial infarction, heart failure, stroke, peripheral vascular disease, cirrhosis, 
hepatitis, gastro-oesophageal reflux disease, peptic ulcer disease), smoking status (never smoker, 
previous smoker or current smoker), alcohol consumption (never, <1 day per week, 1-2 days per 
week, 3-4 days per week or >4 days per week), and other medication use (PPIs, H2RA, nitrates, 
NSAID, and aspirin). BMI (kg/m2 categorized as <25, 25-30, and >30) was calculated from height 
and weight measurements recorded at baseline by trained research staff. The Townsend score based 





We compared the characteristics of cases and control in PCCIU and participants who proceeded to get 
liver cancer and those that did not in UK Biobank using descriptive statistics (e.g., mean, median) for 
continuous variables and frequencies and percentages for categorical variables.  
 
In the PCCIU dataset nested case-control study, we used conditional logistic regression models to 
estimate odd ratios (OR) and associated 95% confidence intervals (CI) for the association between 
statin use and the risk of liver cancer. The matched design accounted for age, sex and GP practice, and 
we adjusted for potential confounders (e.g., smoking, obesity, alcohol consumption, co-morbidities) 
through a series of multivariate analyses. In addition to examining associations with ever/never use of 
statins, we examined associations with statin use according to the number of prescriptions, DDDs, and 
by type of statin therapy. Sensitivity analyses were also conducted removing prescriptions in the 2 
years prior to index date (including only patients with 4 years of medical records), and in the 4 years 
prior to index date (including only patients with 6 years of medical records), to investigate the 
potential for reverse causation potentially due to gastrointestinal symptoms. A further sensitivity 
analysis was conducted adjusting for smoking and alcohol using multiple imputation with chained 
equations.22 First, an imputation model was created using ordered logit models including age, sex, 
statin prescribed, obesity, comorbidity, medication use, separately for cases and controls. Twenty-five 
imputations were conducted and results were combined using Rubin’s rules.23 Another sensitivity 
analysis was performed by not adjusting for diabetes and aspirin use variables. 
 
In contrast to the PCCIU database, the UK Biobank is a prospective cohort design and so the 
association was analyzed using Cox proportional hazards regression models. Age was the underlying 
time scale (individuals were considered at risk from birth and under observation from age at baseline, 
left truncated) and hazard ratios (HR) and associated 95% CIs were calculated for statins use and liver 
cancer risk overall and by histological subtype (HCC based upon ICD 10 code C22.0 and IBDC code 
C22.1). In the adjusted analyses, the model contained age, sex, deprivation, BMI, alcohol, smoking, 
comorbidities at baseline and medication use at baseline. Sensitivity analyses were conducted by 
repeating the analyses starting follow-up at 2 years after baseline (to remove cancers within 2 years, 
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which could have influenced medication prescribing at baseline). Another sensitivity analysis was 
performed by not adjusting for high cholesterol and diabetes variables. 
 
All analyses were performed using Stata 14.0. Statistical significance was determined at α = 0.05, and 




Primary Care Clinical Informatics Unit (PCCIU) database 
Our nested case-control study in PCCIU included 434 cases of liver cancer and 2,103 matched 
controls. The median exposure period was 4.8 years (interquartile range, 3.1-7.3 years) in cases and 
controls. Liver cancer cases were more likely than controls to smoke, consume high levels of alcohol, 
have diabetes, cerebrovascular disease, cerebrovascular accident, liver diseases, and use aspirin and 
PPIs (Table 1). 
 
Overall, similar proportions of cases and controls used statins (25.6% vs 27.2%; Table 2). In the 
unadjusted model, there was no significant association between statin use and risk of liver cancer 
(OR, 0.92; 95% CI, 0.72-1.18) (Table 2). However, in the fully adjusted model, statin use was 
associated with 39% lower risk of liver cancer (fully adjusted OR, 0.61; 95% CI, 0.43-0.87).  
 
Further analyses revealed that differences in history of diabetes and aspirin use confounded this 
association and excluding both these factors from the multivariate model attenuated the inverse 
association with statin use (adjusted HR without aspirin and diabetes, 0.75; 95% CI 0.54-1.03). The 
model that only included diabetes and aspirin adjustment showed a similar association with the main 
analysis (HR adjusted only for aspirin and diabetes, 0.66; 95% CI 0.49-0.89). When we re-categorized 
cases and controls according to both history of diabetes and statin use (neither, diabetes and no statin 
use, no diabetes and statin use, and both diabetes and statin use), and use of aspirin and statins 
(neither, aspirin use and no statin use, no aspirin use and statin use, and both aspirin and statin use), 
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the inverse association with statin use was only observed among those without diabetes (adjusted HR, 
0.69; 95% CI, 0.47-1.00) and those without concurrent aspirin use (adjusted HR, 0.59; 95% CI, 0.34-
1.00).  
 
We found evidence for a dose-response relationship with increased duration of statin exposure 
(compared with never users: 1-11 prescriptions; fully adjusted OR, 0.74; 95% CI, 0.46-1.17; ≥12 
prescriptions; OR, 0.54; 95% CI, 0.36-0.82; p trend 0.003). Associations were similar when exposure 
was based upon DDDs. Finally, the magnitude of the inverse association with risk of liver cancer was 
larger for simvastatin (fully adjusted OR, 0.53; 95% CI, 0.36-0.78) compared to other types of statins 
(Table 2). In a sensitivity analysis, the association with statin use was similar to the main analysis 
after introducing a 2 year (fully adjusted OR, 0.63; 95% CI, 0.42-0.94) or 4 year (fully adjusted OR, 
0.71; 95% CI, 0.40-1.25) lag period. Associations were similar to the main analysis in other 
sensitivity analyses (Table 3). 
 
UK Biobank 
Among 471,851 participants in the UK Biobank, 182 participants developed incident liver cancer (88 
HCC and 72 IBDC cases) over a median follow-up of 4.6 years (interquartile range, 3.9-5.3 years). 
Those who developed liver cancer during follow-up were more likely than those who did not develop 
liver cancer to be older, male, be from deprived areas, smoke, consume high level of alcohol, be 
obese, have diabetes, hypertension, angina, myocardial infarction, heart failure, stroke, cirrhosis, 
hepatitis, and use nitrates, aspirin, PPIs, and H2RA at baseline (Table 1). 
 
Overall, amongst 395,301 statin users 137 developed liver cancer and amongst 76,550 statin non-
users 45 developed liver cancer. In the unadjusted model, there was no significant association 
between statin use and risk of liver cancer (HR, 1.17; 95% CI, 0.83-1.65) (Table 4). However, similar 
to that observed in the PCCIU analysis, in the fully adjusted model, statin use was associated with 
36% lower risk of liver cancer (fully adjusted HR, 0.64; 95% CI, 0.39-1.07), although the association 
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did not achieve statistical significance. The reduced risk was most marked for HCC (adjusted HR, 
0.48; 95% CI, 0.24-0.94) but not for IBDC (adjusted HR, 1.09; 95% CI, 0.45-2.64).  
 
No significant associations were observed between type of statins and risk liver cancer overall, or by 
histological subtype. Further analyses revealed that the reduced risk for liver cancer was largely 
apparent only after controlling for differences in prevalence of diabetes among cases and controls (HR 
adjusted only for diabetes, 0.73; 95% CI 0.49-1.08). In sensitivity analyses (Table 5) introducing a 2 
year lag, the association between statins and liver cancer risk (adjusted HR 0.63, 95% CI 0.36-1.10) 
and HCC risk (adjusted HR 0.57, 95% CI 0.28-1.15) were similar to the main analysis. Finally, a 
sensitivity analysis not adjusting for high cholesterol revealed a slightly more marked inverse 
association between statin use and risk of liver cancer (adjusted HR 0.52, 95% CI 0.33-0.80) and risk 







Using data from two large independent population‐based studies, we found a consistent inverse 
relationship between use of statins and the risk of primary liver cancer, although this was only evident 
for HCC and not IBDC in the UK Biobank analysis. Compared with statin non-users, individuals with 
a history of any statin use had an over 35% lower risk of developing incident liver cancer. 
Importantly, our findings are evident in both study designs (we observed similar results in case-
control vs. prospective cohort study) and method of exposure ascertainment (we observed similar 
results for self-reported data vs. prescription records).  
 
Our results from the PCCIU database nested case-control and UK biobank (particularly for HCC) 
studies are consistent with previous studies. A reduction of liver cancer risk in statin users has been 
observed in meta-analyses11,24,25 with the most recent11 observing a 54% reduction in liver cancer risk 
and a reduction of 14% in liver cancer risk per 50 daily defined doses.  Our study result from PCCIU 
database is similar to a previous study with the same study design in a UK population, that observed a 
reduced liver cancer risk in statins users and similarly, the association followed a dose response.26 
However, our results are an important addition to the literature as this previous UK-based study, 
unlike ours, was unable to verify cancer outcomes through cancer registries and was unable to 
examine associations with specific histological subtypes of liver cancer. 
 
In UK Biobank, the inverse association was less apparent after adjustment for cholesterol, which has 
been shown to reduce liver cancer risk,27 but very few previous studies have adjusted for cholesterol.28 
For IBDC, our study showed no significant association with use of statins. This is not consistent with 
the literature. Two previous case-control studies found consistently reduced risk for bile duct 
carcinoma (adjusted OR 0.87, 95% CI 0.75-1.01)10 and cholangiocarcinoma (adjusted OR 0.80, 95% 
CI 0.71-0.90).29 The difference in the result between our study and two previous studies could be 
explained partly by the limited number of IBDC cases in the UK Biobank database. Moreover, the 
two previous studies investigated cholangiocarcinoma defined as either extra- or intrahepatic bile duct 
carcinoma, while in our study we investigated specifically IBDC. For statin subtypes, only 
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simvastatin was significantly associated with reduced liver cancer risk in PCCIU dataset which might 
be explained by its frequency of use in comparison to other statin types. Although the HR was 
reduced, we did not find a significant association for simvastatin use in UK Biobank. Simvastatin was 
found to be inversely associated with liver cancer in a previous meta-analysis, however, similar 
associations were observed for other statin subtypes. 24 
 
The cause of the observed reduced risk of liver cancer in statin users is unknown. Nevertheless, some 
potential mechanisms for a protective effect of statins on cancer can be suggested. Statins have been 
shown to inhibit the production of mevalonate leading to a reduction in the growth and proliferation 
of neoplastic cells.30 Statins have also been shown to inhibit inflammation30 and angiogenesis,31 which 
play a crucial role in carcinogenesis. Lastly, statins have been shown to induce apoptosis of abnormal 
cells by regulating the signaling pathways including the RAF-MEK-ERK pathway.30 A more specific 
look at mechanism of statins on liver cancer showed that statins might involve the ubiquinone 
inhibition, leading to the apoptosis of preneoplastic liver cells.32 Alternatively, the inverse 
associations could reflect confounding. High cholesterol is the main indication for statin treatment and 
has been shown to be inversely associated with risk of liver cancer.27,33 In UK Biobank we adjusted 
for high cholesterol and the associations with HCC remained, but high cholesterol was based upon 
self-report and we did not have actual cholesterol serum levels and therefore there remains the 
potential for residual confounding by cholesterol. Furthermore, although statins appear safe in patients 
with chronic liver disease,34 it is possible that patients with liver diseases may be less likely to be 
prescribed statins because of their potential hepatotoxicity.35 Our study adjusted for chronic liver 
diseases but we did not have information on liver function tests, which are a known contraindication 
for statins,36 therefore we cannot rule out confounding by liver function test results, as has been seen 
previously.28   
 
Our study has a number of strengths. First, in PCCIU database, information on the number of 
prescriptions, medication dose, and number of pills were available so we could investigate any 
potential dose response relationship between statins and liver cancer. Recall bias was limited because 
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medication use was recorded by GPs. Second, in the UK Biobank, cases were identified by cancer 
registry therefore information of outcome was verified. Details of histological type of liver cancer 
were also provided allowing us to demonstrate that statins were only associated with a reduced 
incidence of HCC. While the medication use was based on self-report, the information was verified by 
a trained nurse. More importantly, in both datasets we have adjusted for a wide range of covariates 
including the main risk factors for liver cancer (age, sex, BMI, smoking and alcohol consumption, 
comorbidities), indications and contraindications of statins (high cholesterol, chronic liver diseases), 
and medications previously shown to be associated with liver cancer risk (metformin37,38, aspirin39, 
beta-blockers40, proton pump inhibitors and histamine-2 receptor antagonist41).   
 
However, our study has a number of limitations. We cannot rule out confounding by incomplete or 
unavailable confounders e.g. cholesterol and liver function tests as previously mentioned. Therefore, 
further studies should aim to collect detailed information on these variables. Furthermore, we cannot 
be sure that participants used the prescribed medications and previous studies have shown evidence of 
non-adherence to statin therapy regimes because of a lack of knowledge about their efficacy and 
concerns about side effects.42 However this information bias seems more likely to drag associations to 
the null rather than to produce the inverse associations we observed. Moreover, as data on histological 
type of liver cancer was not available in PCCIU database we were unable to examine separately the 
association of statin use with risk of HCC and IBDC. A further potential limitation in the PCCIU 
study is that we adjusted for the most recent recorded lifestyle risk factors prior to cancer diagnosis, 
which could lead to inappropriate adjustment if these lifestyle risk factors changed due to a 
predisposing condition such as cirrhosis. 
 
In conclusion, results from our two independent datasets showed a decreased risk of liver cancer 
associated with statin use, which was limited to the HCC subtype in one study. However, whether this 
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